WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the closing of its previously announced underwritten public offering of 16,675,000 shares of its common stock, including 2,175,000 shares sold pursuant to the underwriters' full exercise of their option to purchase

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price of $6.50 per share, before underwriting discounts. In addition, ImmunoGen has granted the underwriters a 30-day option

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN) today announced that it intends to offer and sell, subject to market and other conditions, 13,000,000 shares of its common stock in an underwritten public offering. ImmunoGen also intends to grant the underwriters a 30-day option to

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: Morgan Stanley

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ:IMGN) ("ImmunoGen" or the "Company") today announced that it has entered into privately negotiated exchange agreements with a limited number of holders of its 4.50% Convertible Senior Notes due 2021.

Strengthens Jazz hematology/oncology portfolio with options for innovative development candidates IMGN779 and IMGN632 ImmunoGen to receive a $75 million upfront payment, up to $100 million in research support, a co-commercialization option, and potential future opt-in fees, milestones and royalties

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that David Johnston , chief financial officer, will present at the upcoming Canaccord Genuity Growth Conference .

Data Presented at ASCO Support Broad Potential of Mirvetuximab Soravtansine in Ovarian Cancer Sanofi and Debiopharm Transactions Strengthen Cash Position Conference Call to be Held at 8:00am ET Today WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc .

WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 28, 2017 , to discuss its second quarter

Data demonstrate favorable safety profile with repeat dosing and no dose-limiting toxicities Dose-dependent biological and anti-leukemia activity observed WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the